Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupAnemias, CytopeniasDiseaseSickle Cell DiseaseSubgroupICD10D57.0D57.1D57.2D57.8MeSHAnemia, Sickle CellSequenceCZLZ5, Sickle Cell Disease, C1 (PID1728) -|- CZLZ5, C2+ (PID1729)ChemotherapyChemo-substanceCrizanlizumabHydroxyureaVoxelotorChemo-substanceCrizanlizumabHydroxyureaVoxelotorChemo-substanceCrizanlizumabHydroxyureaVoxelotorChemo-substanceCrizanlizumabHydroxyureaVoxelotorNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionNaCl 0.9%Supportive substanceBalanced Crystalloid SolutionNaCl 0.9%Supportive substanceBalanced Crystalloid SolutionNaCl 0.9%Supportive substanceBalanced Crystalloid SolutionNaCl 0.9%No. Substances2Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlsupportiveRisksArthalgiaConstipationDiarrheaDrowsinessEmetogenicityFatigueHeadacheInfusion ReactionPainPneumoniaPruritusPyrexiaRashUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorAtaga KIQureshi AVichinsky EDiseaseSichelzellerkrankungSichelzellerkrankung, 2 bis 10 Schmerzkrisen in den letzten 12 Monaten, mit oder ohne Therapie mit HydroxyureaSichelzellerkrankung, 2 bis10 Schmerzkrisen in den letzten 12 Monaten, mit oder ohne Therapie mit HydroxyureaSichelzellerkrankung, 12-65 Jahre, Hb-Wert 5,5-10,5 g/dl, 1-10 vasooklusive Krisen in den letzten 12 MonatenOriginOxford Children's Hospital, Oxford University Hospital NHS Trust, OxfordUniversity of California, San Francisco Benioff Children's Hospital Oakland, Oakland, USAUniversity of North Carolina at Chapel Hill, Chapel Hill, USA, SUSTAIN trialProtocols in Revision 4 protocols foundProtocols under revision.Crizanlizumab 5, Sickle Cell Disease, Cycle 1 (PID1728)Crizanlizumab 5, Sickle Cell Disease, Cycle 2+ (PID1729)Hydroxyurea 15, Sickle Cell Disease (PID1747)Voxelotor 1500, Sickle Cell Disease (PID1748)
